Home Stock

Stock Research: Fisher & Paykel Healthcare

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Fisher & Paykel Healthcare

NZC:FPH NZFAPE0001S2
57
  • Value
    11
  • Growth
    97
  • Safety
    Safety
    78
  • Combined
    75
  • Sentiment
    33
  • 360° View
    360° View
    57
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Fisher & Paykel Healthcare Corporation Limited designs, manufactures, and markets products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The company operates in the medical device industry, with products for hospital and homecare settings. It sells its products in over 120 countries worldwide, including Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, and India. In the last fiscal year, the company had a market cap of $12,544 million, profits of $722 million, revenue of $1,148 million, and 7506 employees.

more

ANALYSIS: With an Obermatt 360° View of 57 (better than 57% compared with alternatives), overall professional sentiment and financial characteristics for the stock Fisher & Paykel Healthcare are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Fisher & Paykel Healthcare. The consolidated Growth Rank has a good rank of 97, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 97% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 78 which means that the company has a financing structure that is safer than 78% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 11 which means that the share price of Fisher & Paykel Healthcare is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 89% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 33, which means that professional investors are more pessimistic about the stock than for 67% of alternative investment opportunities. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Growth
Country New Zealand
Industry Health Care Equipment
Size Large
Website fphcare.com
Index
ASX 100
ASX 200
ASX 300
NZSX 50
Fisher & Paykel Healthcare stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 11-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 13 26 19
Growth
97 99 49 33
Safety
Safety
78 75 73 59
Sentiment
33 46 58 37
360° View
360° View
57 78 59 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
38 7 3 19
Opinions Change
41 54 83 50
Pro Holdings
n/a 41 59 40
Market Pulse
11 83 83 69
Sentiment
33 46 58 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
11 13 26 19
Growth
97 99 49 33
Safety Safety
78 75 73 59
Combined
75 79 60 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
5 3 7 13
Price vs. Earnings (P/E)
17 11 14 19
Price vs. Book (P/B)
3 7 7 9
Dividend Yield
43 44 55 45
Value
11 13 26 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
72 77 78 10
Profit Growth
88 70 45 10
Capital Growth
73 98 19 95
Stock Returns
82 91 51 51
Growth
97 99 49 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
74 67 77 72
Refinancing
39 22 20 24
Liquidity
82 100 84 83
Safety Safety
78 75 73 59

Similar Stocks

Discover high‑ranked alternatives to Fisher & Paykel Healthcare and broaden your portfolio horizons.

Omron

TYO:6645
Country: Japan
Industry: Electronic Components
Size: X-Large
Full Stock Analysis

Bridgestone

TYO:5108
Country: Japan
Industry: Tires & Rubber
Size: XX-Large
Full Stock Analysis

Tosoh

TYO:4042
Country: Japan
Industry: Commodity Chemicals
Size: X-Large
Full Stock Analysis

Sinopharm

HKG:1099
Country: China
Industry: Health Care Distributors
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews